- Home
- SLRN vs YMAB Comparison
SLRN vs YMAB Comparison
Compare SLRN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRN
- YMAB
- Stock Information
- Founded
- SLRN 2020
- YMAB 2015
- Country
- SLRN United States
- YMAB United States
- Employees
- SLRN N/A
- YMAB N/A
- Industry
- SLRN Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SLRN Health Care
- YMAB Health Care
- Exchange
- SLRN Nasdaq
- YMAB Nasdaq
- Market Cap
- SLRN 485.6M
- YMAB 482.4M
- IPO Year
- SLRN 2023
- YMAB 2018
- Fundamental
- Price
- SLRN $3.15
- YMAB $8.28
- Analyst Decision
- SLRN Buy
- YMAB Strong Buy
- Analyst Count
- SLRN 4
- YMAB 10
- Target Price
- SLRN $11.75
- YMAB $21.00
- AVG Volume (30 Days)
- SLRN 811.9K
- YMAB 303.4K
- Earning Date
- SLRN 11-13-2024
- YMAB 11-08-2024
- Dividend Yield
- SLRN N/A
- YMAB N/A
- EPS Growth
- SLRN N/A
- YMAB N/A
- EPS
- SLRN N/A
- YMAB N/A
- Revenue
- SLRN N/A
- YMAB $84,553,000.00
- Revenue This Year
- SLRN N/A
- YMAB $6.46
- Revenue Next Year
- SLRN N/A
- YMAB $20.68
- P/E Ratio
- SLRN N/A
- YMAB N/A
- Revenue Growth
- SLRN N/A
- YMAB N/A
- 52 Week Low
- SLRN $3.11
- YMAB $6.29
- 52 Week High
- SLRN $8.89
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- SLRN 26.85
- YMAB 25.63
- Support Level
- SLRN $3.11
- YMAB $9.31
- Resistance Level
- SLRN $3.60
- YMAB $11.10
- Average True Range (ATR)
- SLRN 0.29
- YMAB 0.72
- MACD
- SLRN -0.05
- YMAB -0.09
- Stochastic Oscillator
- SLRN 1.48
- YMAB 7.35
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.